Intarcia’s Implantable Diabetes Drug-Device Combo Gets Public Hearing

Intarcia Therapeutics will continue its seven-year quest for FDA approval of its drug-device diabetes treatment with an alternative form of hearing — a public hearing before an advisory committee on Sept. 21to discuss CDER’s refusal to approve the product.
Source: Drug Industry Daily